Maxim Group restated their buy rating on shares of Sophiris Bio (NASDAQ:SPHS) in a report issued on Wednesday morning. They currently have a $5.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $6.00.
Several other analysts have also recently weighed in on SPHS. HC Wainwright restated a buy rating and set a $6.00 price target on shares of Sophiris Bio in a report on Friday, November 10th. ValuEngine upgraded Sophiris Bio from a strong sell rating to a sell rating in a report on Friday, December 15th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $6.00.
Shares of Sophiris Bio (SPHS) opened at $2.02 on Wednesday. The company has a current ratio of 13.37, a quick ratio of 13.37 and a debt-to-equity ratio of 0.60. Sophiris Bio has a twelve month low of $1.80 and a twelve month high of $2.95.
ILLEGAL ACTIVITY WARNING: This article was first published by Week Herald and is owned by of Week Herald. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://weekherald.com/2018/02/15/sophiris-bio-sphs-given-buy-rating-at-maxim-group.html.
About Sophiris Bio
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.